For thirty years, the immunotherapy field has tried to engineer new immunity, release suppressed immunity, or bypass it altogether.
The training is already done.
The patient just needs a target labeled in a language the immune system already speaks.
We're here to deliver that label.
IMYUN is built by leaders in life science with a proven track record in regulatory, development and commercialization.
Seasoned biotech executive with deep experience in company building, fundraising, strategic growth, and value creation. Expertise in positioning companies for successful transactions at early and non-mature stages.
Inventor of the ITC™ platform. 25+ years in cancer immunology and immune-based therapeutic innovation. PhD from the Weizmann Institute. Prior signal peptide tag system invention, clinically tested, and published in peer-reviewed journals.
Director, Legorreta Cancer Center at Brown University. Associate Dean for Oncologic Sciences. American Cancer Society Research Professor. Discoverer of the p21 tumor suppressor. Global authority in translational oncology.
Decades of translational immunology across cancer and anti-infective indications. Deep expertise in signal peptide-biology and the ITC™ platform. Co-mentor to the junior scientist executing the POC program - day-to-day lab leadership.
Expert in host immune responses to mycobacterial pathogens. Former Director of the TB Program at the Bill & Melinda Gates Foundation. Board Member of Celgene for over 20 years. Research at Rockefeller University led to the discovery of thalidomide analogues in myeloma.
Pioneer in gene therapy, HIV/AIDS, and cancer immunotherapy including mRNA vaccination. Professor of Microbiology & Immunology at the University of Miami, Miller School of Medicine. Advocate for TAP-independent pathways as improved anti-tumor modalities.
We're on a mission to turn pre-existing immunity into a programmable therapy.Leon-Ariel Boston, CEO
We're building more than a platform. We're building a future where solid tumors stop hiding from the immune system.
We follow biology, clinical evidence, and data.
We're looking for top-tier scientists and clinicians ready to build a new generation of immunotherapy. If that sounds like you, we'd love to meet you.